Introduction: COVID-19 has emerged as a global problem with vaccines being established as one of the best tools in its control. Of particular interest in dermatology are risks and manifestations of cutaneous reactions from such countermeasures, with strides made in documenting and associating skin reactions with vaccines against COVID-19. This study aimed to determine the incidence of cutaneous adverse reactions in recipients of recombinant ChAdOx1-S and inactivated SARS-COV-2 vaccines among healthcare personnel and employees of UERMMMCI. Methods: A cross-sectional study was done were respondents, chosen through randomized stratified cluster sampling, were given a questionnaire to elicit cutaneous adverse effects associated with COVID-19 vaccines. Results: There were198 respondents, of which 29.3% were male and 70.7% were female, with a mean age of 26.07 years. Of these respondents, 72 (36.36%) received recombinant ChAdOx1-S and 126 (63.64%) received inactivated SARS-COV-2 vaccine. For the first dose, cutaneous reactions developed in 6 (8.33%) recipients of recombinant ChAdOx1-S, and 2 (1.59%) recipients of inactivated SARS-COV-2. For the second dose, no reactions followed vaccination with recombinant ChAdOx1-S while 4 (3.17%) reactions developed after inactivated SARS-COV-2 vaccination. Lesions were mostly confined to the injection site presenting with erythema for both vaccine types. One urticarial, widespread reaction was associated with a second dose of inactivated SARS-COV-2 vaccine. Conclusions Adverse reactions to COVID-19 vaccinations have been documented which may be attributed to respective excipients rather than vaccine antigens. Due to the rare occurrence of severe anaphylactic reactions, vaccine use is recommended as they confer protection even to those with prior infections. Documented reactions in this study were observed to be mild and self- limiting similar to larger studies.
Vaccines ; COVID-19 ; Pandemics

: Pityriasis lichenoides (PL) is an inflammatory papulosquamous condition that exists in a continuous spectrum that consists mainly of pityriasis lichenoides et varioliformis acuta and pityriasis lichenoides chronica (PLC). The condition has been reported to erupt in response to infections, radiocontrast media, medications and vaccines. Most case reports on vaccine-related eruption involve the acute PL, hence, this report aimed to present a case presenting with lesions of the chronic variant. : A 21-year-old female presented with multiple erythematous to hyperpigmented ill defined plaques, some ulceronecrotic, topped with fine scales and excoriations on the upper and lower extremities, periumbilical area and back of 4 months duration, following rabies vaccinations. : Histopathologic findings, including interface dermatitis, parakeratosis, spongiosis, and mixed inflammatory infiltrates, confirmed the diagnosis of PLC. The patient responded well to oral corticosteroids and heliotherapy. PL is rare and requires additional research. The potential role of vaccination as an etiologic agent represented a crucial area of this investigation. Additionally, heliotherapy should be considered as a viable therapeutic alternative when phototherapy is not feasible.. Further research is needed to elucidate the pathogenesis of PL and establish evidence-based treatment protocols.
Pityriasis lichenoides chronica ; Pityriasis lichenoides ; heliotherapy ; vaccine